Case Control Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Sep 7, 2022; 28(33): 4812-4822
Published online Sep 7, 2022. doi: 10.3748/wjg.v28.i33.4812
Table 1 List of specific sets of primers and probes used for the analysis
Target
Sequence
cссDNAFwCCGTGTGCACTTCGCTTCA
RevGCACAGCTTGGAGGCTTGA
ProbeFAM-CATGGAGACCACCGTGAACGCCC-BHQ1
β-globin-V31-FEP-CE (АmpliSens)
HPV HCR-Screen (AmpliSens)
Table 2 Study population characteristics

PDAC, n = 60
Control, n = 70
Age in yr, Me (25%-75%)64 (59-69)62 (58-65)
Race/Ethnicity
White/Caucasian, n (%)56 (93.3)65 (92.9)
Asian, n (%)4 (6.7)5 (7.1)
Females, n (%)33 (55.0)45 (64.3)
Anti-HBc (total), n (%)18 (30.0)a9 (12.9)
Anti-HBc + anti-HBs, n (%)8 (13.3)5 (7.1)
Anti-HBc (only), n (%)10 (16.7)4 (5.7)
HBV DNA (blood and/or pancreatic tissue), n (%1)8 (44.4)a0
HBV DNA (pancreatic tissue only), n (%1)6 (33.3)a0
Table 3 The results of special examination of subjects with pancreatic ductal adenocarcinoma
No.SexAge in yrBlood samples
Pancreatic tissue
HBsAg
Anti-HBc
Anti-HBs
HBV DNA, IU/mL
HBV DNA, IU/mL
pgRNA HBV, IU/mL
cccDNA, copies/cell × 10-6
HBxAg
HBx-positive cells1, %
1M50NegPosNegTnd653Tnd257Pos3.9
2F58NegPosPosTnd4157971440NpNp
3M60NegPosPosTnd1183TndTndPos3.7
4M61NegPosPosTnd364520314Pos3.4
5F63NegPosPosTndTndTndTndNeg0
6F66NegPosPos134868NpNpNpNp
7M69NegPosPosTnd610TndTndNpNp
8M69NegPosPosTnd30214281384NpNp
9F70NegPosPos126834Tnd1026Pos9.9